Advanced in Hyperthyroidism

Alfredo Pontecorvi

Rome, IT 
Advanced in Hyperthyroidism
Rome, IT 
OverviewLocationsClinical Research

Overview

Alfredo Pontecorvi practices in Rome, Italy. Mr. Pontecorvi is rated as an Advanced expert by MediFind in the treatment of Hyperthyroidism. His top areas of expertise are Hypertrichosis-Acromegaloid Facial Appearance Syndrome, Acromegaloid Facial Appearance Syndrome, Acromegaly, Thyroidectomy, and Hormone Replacement Therapy (HRT).

His clinical research consists of co-authoring 374 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 12 articles in the study of Hyperthyroidism.

Gender
Male

Locations

Rome, Italy
Other Locations
Sacro Cuore, Italy
Milan, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: June 19, 2025
Intervention Type: Drug
Study Drug: Levoketoconazole
Study Phase: Phase 3
A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: November 08, 2022
Intervention Type: Drug
Study Phase: Phase 3
An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome
An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: April 19, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

374 Total Publications

Corrigendum to "Human subjects with impaired beta-cell function and glucose tolerance have higher levels of intra-islet intact GLP-1" [Metabolism, Volume 163 (2025), Article Number 156087].
Corrigendum to "Human subjects with impaired beta-cell function and glucose tolerance have higher levels of intra-islet intact GLP-1" [Metabolism, Volume 163 (2025), Article Number 156087].
Journal: Metabolism: clinical and experimental
Published: September 05, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Pontecorvi's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 31 Advanced Conditions
View All 81 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile